These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Randomized double-blind comparison of the effects of isosorbide dinitrate retard, verapamil sustained-release, and their combination on myocardial ischemic episodes.
    Author: Friedensohn A, Meshulam R, Schlesinger Z.
    Journal: Cardiology; 1991; 79 Suppl 2():31-40. PubMed ID: 1760827.
    Abstract:
    The antianginal and anti-ischemic efficacy of isosorbide dinitrate (ISDN) retard 120, verapamil 120 sustained-release (s.r.) and their combination was evaluated in 30 patients with chronic angina pectoris. The study was a randomized, double-blind crossover comparison. The evaluation was determined by exercise testing and 24-hour electrocardiographic ambulatory monitoring. The sum of ST-segment depression at comparable exercise levels was reduced by 37% (p less than 0.001) after verapamil 120 s.r. and by 45% (p less than 0.001) after combination therapy. After ISDN retard 120 the sum of ST-segment depression was also slightly reduced by 18% without attaining statistical significance. Total walking time and time to angina pectoris during treadmill exercise were significantly prolonged after all treatments. The sum of ST-segment depression in the 24-hour Holter ECG was reduced by 46% (p less than 0.001) after verapamil and by 39% (p less than 0.01) after combined therapy. After ISDN retard 120 the mean reduction was 34% (p less than 0.01). In conclusion, the result of the study indicated that ISDN retard 120, verapamil 120 s.r. and a combination of both drugs are effective in reducing the frequency and duration of ischemic episodes in patients with ischemic heart disease.
    [Abstract] [Full Text] [Related] [New Search]